JP2000512980A5 - - Google Patents

Download PDF

Info

Publication number
JP2000512980A5
JP2000512980A5 JP1998500803A JP50080398A JP2000512980A5 JP 2000512980 A5 JP2000512980 A5 JP 2000512980A5 JP 1998500803 A JP1998500803 A JP 1998500803A JP 50080398 A JP50080398 A JP 50080398A JP 2000512980 A5 JP2000512980 A5 JP 2000512980A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1998500803A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000512980A (ja
Filing date
Publication date
Priority claimed from US08/659,206 external-priority patent/US5922685A/en
Application filed filed Critical
Publication of JP2000512980A publication Critical patent/JP2000512980A/ja
Publication of JP2000512980A5 publication Critical patent/JP2000512980A5/ja
Ceased legal-status Critical Current

Links

JP10500803A 1996-06-05 1997-06-04 腫瘍のil―12遺伝子治療 Ceased JP2000512980A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/659,206 1996-06-05
US08/659,206 US5922685A (en) 1996-06-05 1996-06-05 IL-12 gene therapy of tumors
PCT/US1997/009591 WO1997046263A1 (en) 1996-06-05 1997-06-04 Il-12 gene therapy of tumors

Publications (2)

Publication Number Publication Date
JP2000512980A JP2000512980A (ja) 2000-10-03
JP2000512980A5 true JP2000512980A5 (enExample) 2005-01-13

Family

ID=24644498

Family Applications (1)

Application Number Title Priority Date Filing Date
JP10500803A Ceased JP2000512980A (ja) 1996-06-05 1997-06-04 腫瘍のil―12遺伝子治療

Country Status (6)

Country Link
US (1) US5922685A (enExample)
EP (1) EP0963207B1 (enExample)
JP (1) JP2000512980A (enExample)
DE (1) DE69735643T2 (enExample)
ES (1) ES2262180T3 (enExample)
WO (1) WO1997046263A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998041229A1 (en) * 1997-03-19 1998-09-24 F. Hoffmann-La Roche Ag USE OF IL-12p40 AS IMMUNOSTIMULANT
ES2221717T3 (es) 1997-12-08 2005-01-01 Emd Lexigen Research Center Corp. Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
CN1318092C (zh) * 1998-04-15 2007-05-30 利思进药品公司 含有抗体-细胞因子融合蛋白和血管生成抑制剂的免疫治疗用组合物
AU761520B2 (en) * 1998-09-15 2003-06-05 Genetics Institute, Llc Treatment of Kaposi's Sarcoma with IL-12
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
WO2001010912A1 (en) * 1999-08-09 2001-02-15 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
US20030190305A1 (en) * 1999-09-15 2003-10-09 Wyeth And National Institutes Of Health Treatment of Kaposi's sarcoma with IL-12
US7074210B2 (en) * 1999-10-11 2006-07-11 Felton International, Inc. Universal protector cap with auto-disable features for needle-free injectors
EP1220697B1 (en) 1999-10-11 2004-12-29 Felton International, Inc. Universal anti-infectious protector for needleless injectors
AU778826B2 (en) * 1999-10-29 2004-12-23 Anges Mg, Inc. Gene therapy for diabetic ischemic disease
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
US7887506B1 (en) 1999-11-23 2011-02-15 Pulse Needlefree Systems, Inc. Safety mechanism to prevent accidental patient injection and methods of same
US6770054B1 (en) 1999-11-23 2004-08-03 Felton International, Inc. Injector assembly with driving means and locking means
US7115712B1 (en) 1999-12-02 2006-10-03 Maxygen, Inc. Cytokine polypeptides
JP5179689B2 (ja) * 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
US20020120228A1 (en) * 2000-06-08 2002-08-29 Yuh-Fun Maa Powder compositions
US20040213798A1 (en) * 2000-06-08 2004-10-28 Powderject Vaccines, Inc. Spray-dried alum compositions
CZ2003214A3 (cs) * 2000-06-29 2003-08-13 Merck Patent Gmbh Zesílení odpovědi mediovaných fúzním proteinem protilátka-cytokin kombinovanou léčbou pomocí činidel zvyšujících uptake imunocytokinu
US7255865B2 (en) * 2000-12-05 2007-08-14 Allergan, Inc. Methods of administering botulinum toxin
US20020086036A1 (en) 2000-12-05 2002-07-04 Allergan Sales, Inc. Methods for treating hyperhidrosis
DK1366067T3 (da) * 2001-03-07 2012-10-22 Merck Patent Gmbh Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
BR0209177A (pt) 2001-05-03 2004-10-05 Merck Patent Gmbh Anticorpo especìfico a tumor recombinante e uso do mesmo
CA2349506C (en) * 2001-06-14 2009-12-08 Duke University A method for selective expression of therapeutic genes by hyperthermia
EP1454138B1 (en) * 2001-12-04 2012-01-18 Merck Patent GmbH Immunocytokines with modulated selectivity
ATE471946T1 (de) * 2002-12-17 2010-07-15 Merck Patent Gmbh Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
CA2552590A1 (en) * 2004-01-05 2005-07-21 Emd Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
SI1966238T1 (sl) * 2005-12-30 2012-08-31 Merck Patent Gmbh Variante interlevkina-12P40 z izboljšano stabilnostjo
US7833754B2 (en) * 2006-01-13 2010-11-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services IL-12 for expression in mammalian cell
JP2010539993A (ja) * 2007-10-08 2010-12-24 イントレキソン コーポレーション 遺伝子操作した樹状細胞および癌の治療のための使用
MX340972B (es) 2008-10-08 2016-08-02 Intrexon Corp Celulas manipuladas por ingenieria que expresan multiples inmunomoduladores, y uso de las mismas.
WO2010126766A1 (en) * 2009-04-30 2010-11-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inducible interleukin-12
WO2010147971A2 (en) * 2009-06-15 2010-12-23 New York University Il23 modified viral vector for recombinant vaccines and tumor treatment
PL3458083T3 (pl) 2016-05-18 2023-03-13 Modernatx, Inc. Polinukleotydy kodujące interleukinę-12 (il12) i ich zastosowania
AU2018270111B2 (en) 2017-05-18 2022-07-14 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5015580A (en) * 1987-07-29 1991-05-14 Agracetus Particle-mediated transformation of soybean plants and lines
US5149655A (en) * 1990-06-21 1992-09-22 Agracetus, Inc. Apparatus for genetic transformation
WO1995019799A1 (en) * 1994-01-21 1995-07-27 Agracetus, Inc. Gas driven gene delivery instrument
EP0931156A2 (en) * 1996-10-18 1999-07-28 Valentis Inc. Gene expression and delivery systems and uses

Similar Documents

Publication Publication Date Title
JP2000506430A5 (enExample)
JP2001505442A5 (enExample)
JP2000517343A5 (enExample)
JP2000506815A5 (enExample)
JP2000510733A5 (enExample)
JP2001505109A5 (enExample)
JP2000506627A5 (enExample)
JP2001507965A5 (enExample)
JP2000503117A5 (enExample)
JP2001505363A5 (enExample)
JP2001501312A5 (enExample)
JP2000507485A5 (enExample)
JP2000516485A5 (enExample)
JP2000510735A5 (enExample)
JP2001501596A5 (enExample)
JP2001518066A5 (enExample)
JP2001500952A5 (enExample)
JP2001506602A5 (enExample)
JP2001522482A5 (enExample)
JP2000510661A5 (enExample)
JP2000512849A5 (enExample)
JP2001500142A5 (enExample)
JP2000510181A5 (enExample)
JP2000512956A5 (enExample)
JP2001523981A5 (enExample)